Omthera Pharmaceuticals Inc. thinks Phase III data for Epanova show the omega-3 fatty acid could compete with approved lipid-lowering drugs Lovaza and Vascepa icosapent ethyl in patients who are already taking statins to reduce the risk of cardiovascular disease.

All three are omega-3 fatty acid products containing eicosapentaenoic acid (EPA) and/or docosahexaenoic acid (DHA), both of which lower triglycerides by mechanisms that are not well understood.